Industry
Biotechnology
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Loading...
Open
1.07
Mkt cap
1.8M
Volume
93K
High
1.08
P/E Ratio
-0.62
52-wk high
18.36
Low
0.94
Div yield
N/A
52-wk low
0.70
Portfolio Pulse from Benzinga Newsdesk
September 18, 2023 | 8:17 pm
Portfolio Pulse from Benzinga Newsdesk
August 30, 2023 | 11:59 am
Portfolio Pulse from Benzinga Insights
August 29, 2023 | 6:37 pm
Portfolio Pulse from Benzinga Newsdesk
August 22, 2023 | 11:31 am
Portfolio Pulse from Benzinga Newsdesk
August 15, 2023 | 11:32 am
Portfolio Pulse from Benzinga Insights
August 09, 2023 | 4:27 pm
Portfolio Pulse from Benzinga Insights
August 07, 2023 | 4:13 pm
Portfolio Pulse from Benzinga Insights
August 04, 2023 | 6:06 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2023 | 12:01 pm
Portfolio Pulse from Benzinga Insights
July 26, 2023 | 4:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.